Coronary Artery Disease (CAD)Phase 3EXERRTNCT01618669
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
A Phase 3 study testing Regadenoson and Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in people with Coronary Artery Disease (CAD), run by Astellas Pharma Global Development, Inc. at 69 sites in 4 countries.
Trial summary
The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease (CAD)
- What is being tested?
- Regadenoson and Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,147 participants
- Where
- 69 sitesin 4 countries
- Study dates
- Jun 2012to Dec 2014
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects referred for an exercise or pharmacologic stress test SPECT MPI procedure for the evaluation of coronary artery disease (CAD) are eligible for study participation. Subjects referred for pharmacologic stress should have a reasonable potential of attempting exercise stress. Subject must have one of the following:
- a. Past ischemia on any prior imaging stress test without invasive intervention on the artery subtending this territory
- b. Subject with known CAD who have symptoms similar to previous ischemic symptoms, or recent onset of symptoms or recently worsened symptoms suggestive of ischemia
- c. Diamond Forrester estimated pretest probability of CAD of ≥ 50%
- d. History of most recent coronary artery bypass surgery or most recent percutaneous coronary intervention (PCI) > 10 years (patients who are > 30 days but less than 10 years post coronary artery bypass graft (CABG) or PCI can be included if they meet criteria a, b, or e)
- e. Previously demonstrated 100% occlusion by invasive coronary or computed tomography (CT) angiography without successful intervening revascularization as these foods may alter regadenoson effects
Who cannot join
- Subject has a clinically significant illness, medical condition, or laboratory abnormality
- Female subject who is pregnant or lactating
- Subject is on dialysis for end stage renal disease or has a history of glomerular filtration rate (GFR) < 15 mL/min (calculated using MDRD [Modification of Diet in Renal Disease] formula)
- Subject has a history of coronary revascularization by either PCI or CABG within 1 month prior to the rest myocardial perfusion imaging (MPI)
- Subject has a pacemaker or an implantable cardioverter defibrillator (ICD)
- Subject has a history of acute myocardial infarction (MI) or high risk unstable angina within 30 days prior to the rest MPI or has had cardiac transplantation
Show all 9Show fewer
- Subject has uncontrolled hypertension at any point on Visit 2 prior to exercise testing (i.e., systolic blood pressure (SBP) ≥ 180 or diastolic blood pressure (DBP) ≥ 95 mmHg on two consecutive measurements while at rest).
- Subject has severe aortic stenosis or hypertrophic cardiomyopathy with obstruction or has decompensated congestive heart failure
- Subject has a history of severe respiratory disease including: asthma, chronic obstructive pulmonary disease (COPD) or other bronchospastic reactive airway disease or who is on 24-hour continuous oxygen
Trial locations and contacts
69 sites in 4 countries.
69 sites in 4 countries
United States60 sites
St. Joseph's Hospital
Atlanta, Georgia, 30342
University Cardiology Associates, LLC
Augusta, Georgia, 30901
Elite Research and Clinical Trials
Aventura, Florida, 33180
University of Maryland
Baltimore, Maryland, 21207
Massachusetts General Hospital
Boston, Massachusetts, 02114
University of Virginia
Charlottesville, Virginia, 22908
Rush University Medical Center
Chicago, Illinois, 60612
Henry Ford Hospital
Detriot, Michigan, 48202
Wayne State University
Detroit, Michigan, 48201
S & W Clinical Research
Fort Lauderdale, Florida, 33306
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Florida Heart Associates
Fort Myers, Florida, 33907
Silicon Valley Medical Imaging
Fremont, California, 94538
I U School of Medicine/ Krannert Institute of Cardiology
Indianapolis, Indiana, 46202
East Coast Institute for Research, LLC
Jacksonville, Florida, 32216
St. Luke's Cardiology St. Vincent's HealthCare
Jacksonville, Florida, 32216
Cardiovascular Imaging Technologies
Kansas City, Missouri, 64111
Katy Cardiology Associates
Katy, Texas, 77493
Watson Medical Clinic/Lakeland Regional Medical Clinic
Lakeland, Florida, 33805
Las Vegas Radiology
Las Vegas, Nevada, 89113
Laurelton Medical center
Laurelton, New York, 11422
Long Beach Memorial Medical Center
Long Beach, California, 90806
Cedars-Sinai Medical Center
Los Angeles, California, 90048
VA Greater Los Angeles Healthcare System
Los Angeles, California, 90073
Westside Medical Associates of Los Angeles
Los Angeles, California, 90211
Ventura Clinical Trials
Malibu, California, 90265
MIMA Century Research Associates
Melbourne, Florida, 32901
Cardiovascular Research Center of South Florida
Miami, Florida, 33173
Hennepin County Medical Center
Minneapolis, Minnesota, 55455
Mission Internal Medical Group
Mission Viejo, California, 92691
Mobile Heart Specialists, PC
Mobile, Alabama, 36608
Mission Research Institute LLC
New Braunfels, Texas, 78130
HOCC - New Britain Campus
New Britain, Connecticut, 06050
Yale University
New Haven, Connecticut, 06510
Columbia University Medical Center
New York, New York, 10032
Alfieri Cardiology
Newark, Delaware, 19713
Alegent Health Heart and Vascular Specialists
Omaha, Nebraska, 68124
Alegent Health Research Center
Omaha, Nebraska, 68124
Florida Hospital/Cardiovascular Institute
Orlando, Florida, 32803
Midwest Cardiology Associates
Overland Park, Kansas, 66209
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
Berkshire Medical Center
Pittsfield, Massachusetts, 01201
Maine Research Associates
Portland, Maine, 04210
Roanoke Heart Institute, PC
Roanoke, Virginia, 24014
VA San Diego Healthcare System
San Diego, California, 92161
Santa Rosa Cardiology Medical Group, Inc.
Santa Rosa, California, 95405
South Coast Medical Group
Savannah, Georgia, 31406
University of Washington
Seattle, Washington, 98195
Washington University School of Medicine
St Louis, Missouri, 63110
University of South Florida
Tampa, Florida, 33620
West Houston Area Clinical Trial Consultants, LLC
Tomball, Texas, 77375
Los Angeles Biomedical Research Institute
Torrance, California, 22908
Cardiology Associates of North Mississippi
Tupelo, Mississippi, 38801
Westchester Medical Center-New York Medical College
Valhalla, New York, 10595
Cardiology Partners Clinical Research Institute
Wellington, Florida, 33449
Buffalo Cardiology & Pulmonary Associates, P.C.
Williamsville, New York, 14221
Delaware Clinical Trials
Wilmington, Delaware, 19808
Berks Cardiologists, Ltd.
Wyomissing, Pennsylvania, 19610
Michigan Heart
Ypsilanti, Michigan, 48197
Argentina5 sites
Instituto Oulton
Córdoba, X5000JJS
Instituto de Cardiologia la Plata
La Plata, B1925XAC
Hospital Italiano de La Plata
Provincia de Buenos Aires, B1900AX
Hospital Italiano Garibaldi
Rosario, Santa Fe Province, S2000ODA
Sanatorio San Geronimo
Santa Fe, S3001XAF
Peru3 sites
Clinica Anglo Americana
Lima, Lima 27
Hospital Arzobispo Loayza
Lima
Instituto Nacional Cardiovascular de EsSalud
Lima
About this study
Official title: A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential regadenoson SPECT images without exercise.
- Conditions
- Coronary Artery Disease (CAD)
- Being tested
- Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Keywords
- Coronary Artery Disease (CAD), regadenoson, pharmacologic stress
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RegadenosonDrug
Also called Lexiscan, CVT3146
Administered as an intravenous (IV) bolus
Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)Procedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Regadenoson After Peak Exercise | Experimental | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. Receives: Drug: Regadenoson; Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) |
| Regadenoson Alone | Active comparator | On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. Receives: Drug: Regadenoson; Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans
SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect.
The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia.
Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits.
Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.
Measured: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)
Secondary outcomes (11)
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
A clinically significant cardiac event is defined as:
- Any of the following events found on the Holter electrocardiogram (ECG)/12-Lead ECG within 1 hour after regadenoson administration:
- ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, ventricular flutter),
- ST-T depression (> 2 mm),
- ST-T elevation (≥1 mm),
- Atrioventricular (AV) block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block)
- sinus arrest > 3 seconds in duration
Or
- a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction
Or
- a TEAE preferred term of angina unstable within 24 hours of regadenoson administration.
Measured: Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson
Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans
The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated.
Measured: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)
Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans
The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI.
Measured: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans
The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
- 0: normal perfusion
- 1: slightly reduced contrast/radiotracer uptake
- 2: moderately reduced contrast/radiotracer uptake
- 3: severely reduced contrast/radiotracer uptake
- 4: absent contrast/radiotracer uptake.
The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.
Measured: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
- 0: normal perfusion
- 1: slightly reduced contrast/ uptake
- 2: moderately reduced contrast/uptake
- 3: severely reduced contrast/uptake
- 4: absent contrast/uptake.
SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS - SRS).
The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.
Measured: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)
Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category.
Measured: Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)
Overall Assessment of Image Quality
The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan.
Measured: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)
Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference).
Measured: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
Percentage of Scans With Subdiaphragmatic Interference
Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference.
Measured: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported.
Measured: Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes:
- Results in death,
- Is life threatening,
- Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions,
- Results in congenital anomaly, or birth defect,
- Requires inpatient hospitalization or leads to prolongation of hospitalization
- Other medically important events.
Relationship to study drug was assessed by the investigator.
Measured: Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2012 (estimated)
- Study startJun 2012
- Primary completionDec 2014
- Study completionDec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery Disease (CAD)Studies of the same condition, open and under way.
- More trials run by Astellas Pharma Global Development, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,147 participants (actual)
Sponsor and investigators
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Senior Medical Director, Study director, Astellas Pharma Global Development, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01618669
- Sponsor's protocol ID
- 3606-CL-3004
- Acronym
- EXERRT
- Status last verified
- Jan 2016
- First submitted
- 29 May 2012
- Last updated
- 8 Feb 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Thomas GS, Cullom SJ, Kitt TM, Feaheny KM, Ananthasubramaniam K, Gropler RJ, Jain D, Thompson RC. The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol. J Nucl Cardiol. 2017 Jun;24(3):788-802. doi: 10.1007/s12350-017-0813-3. Epub 2017 Feb 21.
PubMed 28224449
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
- ClinicalTrials.gov ID
- NCT01618669
- Acronym / sponsor ID
- EXERRT / 3606-CL-3004
- Conditions
- Coronary Artery Disease (CAD)
- Keywords
- Coronary Artery Disease (CAD), regadenoson, pharmacologic stress
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,147 participants (actual)
- Lead sponsor
- Astellas Pharma Global Development, Inc.Industry (pharma, biotech, devices)
- Study start
- Jun 2012
- Primary completion
- Dec 2014 (actual)
- Study completion
- Dec 2014 (actual)
- First posted
- 13 Jun 2012 (estimated)
- Results
- Posted 8 Feb 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential regadenoson SPECT images without exercise.
Study design
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Regadenoson After Peak Exercise | Experimental | Drug: Regadenoson, Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
| Regadenoson Alone | Active comparator | Drug: Regadenoson, Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Subjects referred for an exercise or pharmacologic stress test SPECT MPI procedure for the evaluation of coronary artery disease (CAD) are eligible for study participation. Subjects referred for pharmacologic stress should have a reasonable potential of attempting exercise stress. Subject must have one of the following:
Key exclusion criteria (9 listed)
- Subject has a clinically significant illness, medical condition, or laboratory abnormality
- Female subject who is pregnant or lactating
- Subject is on dialysis for end stage renal disease or has a history of glomerular filtration rate (GFR) < 15 mL/min (calculated using MDRD [Modification of Diet in Renal Disease] formula)
- Subject has a history of coronary revascularization by either PCI or CABG within 1 month prior to the rest myocardial perfusion imaging (MPI)
- Subject has a pacemaker or an implantable cardioverter defibrillator (ICD)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RegadenosonAlso: Lexiscan, CVT3146Administered as an intravenous (IV) bolus | Drug | Regadenoson After Peak Exercise, Regadenoson Alone |
| Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) | Procedure or surgery | Regadenoson After Peak Exercise, Regadenoson Alone |
Primary outcome
Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans
Time frame: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)
SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia. Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits. Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.
11 secondary outcomes
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Time frame: Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson
Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans
Time frame: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)
Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans
Time frame: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans
Time frame: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
Time frame: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)
Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
Time frame: Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)
Overall Assessment of Image Quality
Time frame: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)
Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
Time frame: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)
Percentage of Scans With Subdiaphragmatic Interference
Time frame: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Time frame: Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Time frame: Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 28224449Thomas GS, Cullom SJ, Kitt TM, Feaheny KM, Ananthasubramaniam K, Gropler RJ, Jain D, Thompson RC. The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol. J Nucl Cardiol. 2017 Jun;24(3):788-802. doi: 10.1007/s12350-017-0813-3. Epub 2017 Feb 21.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease (CAD)
Active, not recruitingPhase 4
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Coronary Artery Disease
Not yet recruiting
Effect of Propionic Acid Supplementation on Endothelial Function
Cardiovascular Diseases, Endothelial Dysfunction
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
RecruitingObservational study
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Testicular Cancer, Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Senior Medical Director study director
Astellas Pharma Global Development, Inc.
69 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Regadenoson and Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in people with Coronary Artery Disease (CAD), run by Astellas Pharma Global Development, Inc. at 69 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 69 sites in United States, Argentina, Peru, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Feb 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans (time frame: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01618669, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2016.